Liquidia Signs Exclusive Licensing Agreement With Vectura for Treprostinil Products in US
Liquidia Corporation announced that its wholly owned subsidiary, Liquidia Technologies, Inc., has entered into an exclusive licensing agreement with Vectura Limited. Under the terms of the agreement, Liquidia Technologies will pay Vectura an upfront payment of $2 million, development milestone payments of up to $12 million, and sales milestone payments of up to $92.5 million, in addition to royalty payments at rates in the middle single digits based on commercial sales in the United States. The agreement grants Liquidia Technologies the exclusive right to develop, manufacture, and commercialize products containing treprostinil, including the L606 product, administered via Vectura's nebulizer device for the treatment of hypertension and interstitial lung diseases. Vectura will be responsible for manufacturing and supplying the device. The agreement includes provisions for termination by either party under certain conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-104000), on October 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.